Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

Por Cheah, Chan Yoon, Nastoupil, Loretta J., Neelapu, Sattva S., Forbes, Sheryl G., Oki, Yasuhiro, Fowler, Nathan H.
Publicado no Blood (2015)